Ginkgo Bioworks Holdings, Inc. (DNA)Healthcare | Biotechnology | Boston, United States | NYSE
11.76 USD
-0.03
(-0.254%) ⇩
(Oct. 13, 2026, 4 p.m.
EDT)
After hours: 11.74 -0.02 (-0.020%) ⇩ (Oct. 13, 2026, 7:53 p.m. EDT) |
Hot Take ↕ | Oct. 10, 2026, 10:36 a.m. EDT
The fundamental reality here is stark: this biotech giant is in a multi-year freefall, having lost over 96% of its value since 2021. Despite a recent year-over-year price recovery, the underlying business is bleeding cash, reporting negative revenue growth, and carrying a negative forward P/E. The balance sheet is fragile with debt exceeding cash reserves, and management is actively selling shares, which undermines any narrative of stability. While the autonomous lab pivot offers a theoretical path to relevance, the market has already punished the stock severely, and the current price reflects deep skepticism about execution. There is no dividend to provide income, and the high beta amplifies the risk of further downside. This is a speculative turnaround play with no margin of safety, suitable only for investors willing to accept the possibility of total capital loss in exchange for a lottery ticket on a successful pivot. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.116841 |
| AutoETS | 0.119112 |
| MSTL | 0.119556 |
| AutoARIMA | 0.159037 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 25% |
| H-stat | 5.86 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 1.56 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 96.152 |
| Revenue per Share | 2.26 |
| Market Cap | 791,921,728 |
| Forward P/E | -4.06 |
| Beta | 1.80 |
| Profit Margins | -219.61% |
| Website | https://www.ginkgo.bio |
As of Oct. 10, 2026, 10:36 a.m. EDT: Speculators are positioning for continued volatility rather than a clear directional breakout. Call Open Interest is heavily concentrated at the $13 strike (near current price) and the $15 strike, suggesting a 'straddle' or 'strangle' bias where traders bet on a move away from the mean without committing to a specific side. Put volume is also significant at the $10 and $11 strikes, indicating a floor is being established there. The massive disparity in implied volatility for deep out-of-the-money calls versus puts suggests fear of a sharp spike is priced in, but the lack of directional skew implies uncertainty dominates sentiment.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.25521165 |
| Address1 | 27 Drydock Avenue |
| Address2 | 8th Floor |
| All Time High | 634.56 |
| All Time Low | 5.0 |
| Ask | 0.0 |
| Ask Size | 400 |
| Audit Risk | 7 |
| Average Daily Volume10 Day | 5,195,230 |
| Average Daily Volume3 Month | 1,899,114 |
| Average Volume | 1,899,114 |
| Average Volume10Days | 5,195,230 |
| Beta | 1.795 |
| Bid | 0.0 |
| Bid Size | 300 |
| Board Risk | 10 |
| Book Value | 6.597 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 10 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.76 |
| Current Ratio | 4.572 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 12.4499 |
| Day Low | 11.51 |
| Debt To Equity | 96.152 |
| Display Name | Ginkgo Bioworks |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,785,960,000 |
| Earnings Call Timestamp Start | 1,785,960,000 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,908,800 |
| Earnings Timestamp Start | 1,793,908,800 |
| Ebitda | -261,624,992 |
| Ebitda Margins | -1.97571 |
| Enterprise To Ebitda | -3.417 |
| Enterprise To Revenue | 6.75 |
| Enterprise Value | 893,871,680 |
| Eps Current Year | -2.93 |
| Eps Forward | -2.9 |
| Eps Trailing Twelve Months | -5.06 |
| Esg Populated | 0 |
| Exchange | NYQ |
| Exchange Data Delayed By | 20 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 8.6496 |
| Fifty Day Average Change | 3.1104002 |
| Fifty Day Average Change Percent | 0.35960045 |
| Fifty Two Week Change Percent | -25.521166 |
| Fifty Two Week High | 18.22 |
| Fifty Two Week High Change | -6.459999 |
| Fifty Two Week High Change Percent | -0.3545554 |
| Fifty Two Week Low | 5.37 |
| Fifty Two Week Low Change | 6.3900003 |
| Fifty Two Week Low Change Percent | 1.1899443 |
| Fifty Two Week Range | 5.37 - 18.22 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,618,839,000,000 |
| Float Shares | 49,880,290 |
| Forward Eps | -2.9 |
| Forward P E | -4.0551724 |
| Free Cashflow | -72,398,248 |
| Full Exchange Name | NYSE |
| Full Time Employees | 485 |
| Fullday Change | -0.03999996 |
| Fullday Change Percent | -0.33927023 |
| Fullday Price | 11.76 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.68042 |
| Gross Profits | 90,102,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04429 |
| Held Percent Institutions | 0.73705 |
| Implied Shares Outstanding | 67,340,277 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,724,112,000 |
| Last Split Factor | 1:40 |
| Long Business Summary | Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts. |
| Long Name | Ginkgo Bioworks Holdings, Inc. |
| Market | us_market |
| Market Cap | 791,921,728 |
| Market State | PREPRE |
| Max Age | 86,400 |
| Message Board Id | finmb_130407341 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -309,639,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 577,779,576 |
| Number Of Analyst Opinions | 2 |
| Open | 11.79 |
| Operating Cashflow | -170,243,008 |
| Operating Margins | -2.84987 |
| Overall Risk | 10 |
| Phone | 877 422 5362 |
| Post Market Change | -0.020000458 |
| Post Market Change Percent | -0.17007191 |
| Post Market Price | 11.74 |
| Post Market Time | 1,791,935,609 |
| Previous Close | 11.79 |
| Price Eps Current Year | -4.013652 |
| Price Hint | 2 |
| Price To Book | 1.7826284 |
| Price To Sales Trailing12 Months | 5.9803333 |
| Profit Margins | -2.19605 |
| Quick Ratio | 4.333 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | -0.0299997 |
| Regular Market Change Percent | -0.254451 |
| Regular Market Day High | 12.4499 |
| Regular Market Day Low | 11.51 |
| Regular Market Day Range | 11.51 - 12.4499 |
| Regular Market Open | 11.79 |
| Regular Market Previous Close | 11.79 |
| Regular Market Price | 11.76 |
| Regular Market Time | 1,791,921,602 |
| Regular Market Volume | 1,861,148 |
| Return On Assets | -0.16718 |
| Return On Equity | -0.59936 |
| Revenue Growth | -0.485 |
| Revenue Per Share | 2.26 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 10 |
| Shares Outstanding | 55,383,808 |
| Shares Percent Shares Out | 0.1086 |
| Shares Short | 7,315,221 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 6,865,017 |
| Short Name | Ginkgo Bioworks Holdings, Inc. |
| Short Percent Of Float | 0.1364 |
| Short Ratio | 3.9 |
| Source Interval | 15 |
| State | MA |
| Symbol | DNA |
| Target High Price | 11.0 |
| Target Low Price | 5.0 |
| Target Mean Price | 8.0 |
| Target Median Price | 8.0 |
| Total Cash | 302,163,008 |
| Total Cash Per Share | 4.487 |
| Total Debt | 404,112,992 |
| Total Revenue | 132,421,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -5.06 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 8.44565 |
| Two Hundred Day Average Change | 3.3143501 |
| Two Hundred Day Average Change Percent | 0.3924328 |
| Type Disp | Equity |
| Volume | 1,861,148 |
| Website | https://www.ginkgo.bio |
| Zip | 2,210 |